MGMT and glioblastoma: Across 9430 TCGA tumors, TARGETS faithfully recapitulated every FDA-approved biomarker–drug pairing (e.g., EGFR-mutant LUAD with EGFR TKIs, p < 0.0001; MGMT-methylated GBM with temozolomide, p < 0.0001) [125].